Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

Gauvreau et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d92360da3af5b1d0835c40 — DOI: https://doi.org/10.1183/13993003.01193-2022

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Severe asthma—A population study perspective· 2019 · 96 citations
2. The Global Lung Function Initiative (GLI) Network: bringing the world’s respiratory reference values together· 2017 · 249 citations
3. Efficacy and Safety of an Inhaled Anti-TSLP Antibody Fragment in Adults with Mild Atopic Asthma· 2020 · 21 citations
4. T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma· 2009 · 1,806 citations
5. Cloning of the Murine Thymic Stromal Lymphopoietin (Tslp) Receptor· 2000 · 414 citations